PsorX (CE-IVD) – a breakthrough for inflammatory skin diseases
PsorX detects the molecular signature of psoriasis versus eczema supporting the reliable differential diagnosis of these diseases.
Based on the gene expression of NOS2 and CCL27, PsorX accurately and efficiently distinguishes these diseases, even in cases where conventional diagnostic methods failed¹
².’

Psoriasis
“Significant knowledge regarding psoriasis and advancement in psoriasis treatment have been gained over the past 30 years. Despite this, in review of the currently available highest level of evidence, the expert work group acknowledges that much has yet to be learned…There is also an important need to identify biomarkers that can potentially predict the appropriate biologic agent for individual patients.” ³
Background

Pipeline products

PatternX
Background
PredX
Background
“For atopic dermatitis and psoriasis, a broad spectrum of innovative treatments has been developed. However, treatment responses cannot be predicted so far. Hence, development of (bio)markers allowing selection of specific medications for individual patients is needed.” ⁶
Mycosis fungoides
(PsorX 2.0)
Background
“The diagnosis of early MF (patch stage) is particularly challenging […] This diagnosis might be elusive because MF in its early stage shares clinical and histopathological features with inflammatory benign dermatoses…and immunohistochemistry and molecular analysis have limited utility as isolated criteria" ⁷
References
- Garzorz, N., L. Krause, F. Lauffer, A. Atenhan, J. Thomas, S. P. Stark, R. Franz, S. Weidinger, A. Balato, N. S. Mueller, F. J. Theis, J. Ring, C. B. Schmidt-Weber, T. Biedermann, S. Eyerich and K. Eyerich (2016). "A novel molecular disease classifier for psoriasis and eczema." Exp Dermatol.
- Quaranta, M., B. Knapp, N. Garzorz, M. Mattii, V. Pullabhatla, D. Pennino, C. Andres, C. Traidl-Hoffmann, A. Cavani, F. J. Theis, J. Ring, C. B. Schmidt-Weber, S. Eyerich and K. Eyerich (2014). "Intraindividual genome expression analysis reveals a specific molecular signature of psoriasis and eczema." Sci Transl Med 6(244): 244ra290.
- Menter, A., B. E. Strober, D. H. Kaplan, D. Kivelevitch, E. F. Prater, B. Stoff, A. W. Armstrong, C. Connor, K. M. Cordoro, D. M. R. Davis, B. E. Elewski, J. M. Gelfand, K. B. Gordon, A. B. Gottlieb, A. Kavanaugh, M. Kiselica, N. J. Korman, D. Kroshinsky, M. Lebwohl, C. L. Leonardi, J. Lichten, H. W. Lim, N. N. Mehta, A. S. Paller, S. L. Parra, A. L. Pathy, R. N. Rupani, M. Siegel, E. B. Wong, J. J. Wu, V. Hariharan and C. A. Elmets (2019). "Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with biologics." J Am Acad Dermatol 80(4): 1029-1072.
- Kolesnik, M., I. Franke, A. Lux, S. R. Quist and H. P. Gollnick (2018). "Eczema in Psoriatico: An Important Differential Diagnosis Between Chronic Allergic Contact Dermatitis and Psoriasis in Palmoplantar Localization." Acta Derm Venereol 98(1): 50-58.
- Gromova, M., A. Vaggelas, G. Dallmann and D. Seimetz (2020). "Biomarkers: Opportunities and Challenges for Drug Development in the Current Regulatory Landscape." Biomark Insights 15: 1177271920974652.
- Ujiie, H., D. Rosmarin, M. P. Schon, S. Stander, K. Boch, M. Metz, M. Maurer, D. Thaci, E. Schmidt, C. Cole, K. T. Amber, D. Didona, M. Hertl, A. Recke, H. Grasshoff, A. Hackel, A. Schumann, G. Riemekasten, K. Bieber, G. Sprow, J. Dan, D. Zillikens, T. Sezin, A. M. Christiano, K. Wolk, R. Sabat, K. Kridin, V. P. Werth and R. J. Ludwig (2022). "Unmet Medical Needs in Chronic, Non-communicable Inflammatory Skin Diseases." Front Med (Lausanne) 9: 875492.
- Torres-Cabala, C. A. (2020). "Diagnosis of T-cell lymphoid proliferations of the skin: putting all the pieces together." Mod Pathol 33(Suppl 1): 83-95.